Zobrazeno 1 - 10
of 36
pro vyhledávání: '"S. E. Coutre"'
Autor:
Paul M. Barr, Tadeusz Robak, Carolyn Owen, Fritz Offner, Peter Hillmen, S. E. Coutre, Jianyong Li, Osnat Bairey, Sebastian Grosicki, D. Simpson, James P. Dean, Alessandra Tedeschi, Jan A. Burger, Helen McCarthy, Carol Moreno, S. Dai, S. Devereux, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Leuk Lymphoma
Moxetumomab pasudotox (Moxe) is a bacterial toxin–based drug consisting of an anti-CD22 immunoglobulin variable domain genetically joined to Pseudomonas exotoxin (PE38) [1]. The drug was approved i...
Autor:
Carolyn Owen, Fritz Offner, Jianyong Li, Sandra Dai, Alessandra Tedeschi, Osnat Bairey, Carol Moreno, Jan A. Burger, Stephen Devereux, Paolo Ghia, Paul M. Barr, Peter Hillmen, S. E. Coutre, Sebastian Grosicki, Helen McCarthy, Anita Szoke, Tadeusz Robak, James P. Dean, Thomas J. Kipps
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S316
Objective: Report RESONATE-2 phase 3 study extended long-term follow-up of first-line ibrutinib vs chlorambucil in older patients with CLL/SLL. Methods: Patients (≥65 years [y]) with previously untreated CLL/SLL (without del[17p]) were randomly ass
Autor:
Michaela Liedtke, Gabriel N. Mannis, Ilana R. Yurkiewicz, Lori Muffly, Suravi Raychaudhuri, S. E. Coutre, Bruno C. Medeiros
Publikováno v:
Journal of Clinical Oncology. 39:e19005-e19005
e19005 Background: CALGB 10403 is a pediatric-inspired ALL regimen that has recently been shown to have improved survival rates in adolescents and young adults with ALL when compared to historical outcomes with traditional adult ALL regimens (Stock e
Autor:
Anita Szoke, Carol Moreno, Paul M. Barr, Fritz Offner, Sandra Dai, Jan A. Burger, Jianyong Li, Stephen Devereux, Osnat Bairey, Carolyn Owen, Helen McCarthy, Sebastian Grosicki, S. E. Coutre, Tadeusz Robak, James P. Dean, Thomas J. Kipps, David Simpson, Alessandra Tedeschi, Peter Hillmen, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 39:7523-7523
7523 Background: Ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor, is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized phase 3 studies versus established t
Autor:
John C. Byrd, Laura Fogliatto, Priti Patel, Ann Janssens, Jeff Porter Sharman, Karin Karlsson, Patricia F. Walker, William G. Wierda, John M. Pagel, Alan P Skarbnik, Gillian Corbett, Min Hui Wang, Versha Banerji, Talha Munir, Paolo Ghia, S. E. Coutre, Miklos Egyed, Yair Herishanu, Wojciech Jurczak, Manali Kamdar
Publikováno v:
Journal of Clinical Oncology. 39:7509-7509
7509 Background: Early results from ELEVATE-TN (NCT02475681) at a median follow-up of 28.3 mo demonstrated superior efficacy of acalabrutinib (A) ± obinutuzumab (O) compared with O + chlorambucil (Clb) in patients (pts) with treatment-naïve (TN) ch
Autor:
Nishitha Reddy, L. Gau, Betty Y. Chang, Richard R. Furman, D.F. James, Susan O'Brien, Constantine S. Tam, John C. Byrd, Ulrich Jaeger, Peter Hillmen, Jennifer R. Brown, Sven DeVos, Paul M. Barr, Marco Montillo, Talha Munir, Federico Caligaris-Cappio, Emily Hsu, Stephen P. Mulligan, Florence Cymbalista, John M. Pagel, Julio Delgado, D. Chung, Carol Moreno, Thomas J. Kipps, Patrick Thornton, Jennifer H. Lin, Jan A. Burger, Jaqueline C. Barrientos, S. E. Coutre, George Cole
Publikováno v:
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Universitat Pompeu Fabra
Leukemia
Leukemia, vol 32, iss 1
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Universitat Pompeu Fabra
Leukemia
Leukemia, vol 32, iss 1
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We r
Autor:
Anil Londhe, Paul M. Barr, Mei Cheng, S. Stilgenbauer, Marie-Sarah Dilhuydy, Asher Chanan-Khan, Carol Moreno, Michelle Mahler, Graeme Fraser, Thomas J. Kipps, M. Salman, Angela Howes, John C. Byrd, Michael Hallek, Susan O'Brien, Jennifer R. Brown, Ulrich Jaeger, D.F. James, J. Ninomoto, Peter Hillmen, Paula Cramer, Jaqueline C. Barrientos, S. E. Coutre
Publikováno v:
Hematological Oncology. 35:109-111
Autor:
Jennifer A. Woyach, John C. Byrd, Jeremy S. Abramson, Amy S. Ruppert, Danielle M. Brander, Richard A. Larson, Jennifer R. Brown, Sreenivasa Nattam, S. E. Coutre, Richard F. Little, Scott E. Smith, Richard Stone, Allison M Booth, Nancy L. Bartlett, Mark R. Litzow, Charles S. Kuzma, Harry P. Erba, Sumithra J. Mandrekar, Wei Ding, Carolyn Owen
Publikováno v:
Journal of Clinical Oncology. 38:e20004-e20004
e20004 Background: IB is a Bruton’s tyrosine kinase inhibitor that showed superior progression-free survival compared with BR in CLL patients (pts) 65 years or older in a randomized phase 3 trial (Woyach et al, NEJM 2018). Pts receiving IB had high
Autor:
P. Hillmen, Carolyn Owen, Thomas J. Kipps, Carol Moreno, I. Lal, James P. Dean, Jan A. Burger, S. Dai, P. Ghia, Fritz Offner, Jianyong Li, Sebastian Grosicki, A. Tedeschi, S. Devereux, S. E. Coutre, Osnat Bairey, Helen McCarthy, Paul M. Barr, Tadeusz Robak, D. Simpson
Publikováno v:
HemaSphere. 3:5-6